Tang Capital Management’s C4 Therapeutics CCCC Stock Holding History

Tang Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-900,000	Closed	-$2M	–	97
2025 Q3	$2M	Hold	900,000	–	–	0.08%	128
2025 Q2	$1.29M	Hold	900,000	–	–	0.07%	143
2025 Q1	$1.44M	Hold	900,000	–	–	0.08%	139
2024 Q4	$3.24M	Buy	900,000 +200,000	+29%	+$994K	0.21%	90
2024 Q3	$3.99M	Buy	700,000 +500,000	+250%	+$3.01M	0.29%	83
2024 Q2	$924K	Buy	+200,000	New	+$1.19M	0.09%	96

Other funds holding CCCC

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Tang Capital Management's CCCC Position: Q4 2025 in Review

Tang Capital Management sold out of C4 Therapeutics (CCCC) in Q4 2025, closing a stake of 900,000 shares — an estimated $2M sold.

Tang Capital Management first reported a position in CCCC in Q2 2024 and held it in 6 quarters. The position peaked at $3.99M in Q3 2024. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

Tang Capital Management reported no remaining C4 Therapeutics position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 900,000 C4 Therapeutics shares in Q4 2025, an estimated $2M.
Tang Capital Management first reported a position in C4 Therapeutics in Q2 2024 and held it in 6 quarters.
Tang Capital Management's C4 Therapeutics position peaked at $3.99M in Q3 2024.
101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.